Most Read Articles
Jairia Dela Cruz, 5 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 22 hours ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.

Valve-in-valve TAVR may replace surgical re-replacement in aortic bioprosthesis failure

08 Aug 2020
In intermediate risk patients, the TAVR is found to have better outcomes

Valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) leads to better short-term outcomes than redo surgical aortic valve replacement (SAVR) in patients treated for aortic bioprosthesis failure, a recent study has shown. During long-term follow-up, no difference is seen in major cardiovascular outcomes between the two treatment arms.

To assess the outcomes of VIV TAVR compared with redo SAVR, the investigators collected data on patients treated for aortic bioprosthesis failure using the French administrative hospital-discharge database between 2010 and 2019. Outcomes were analysed using propensity score matching.

Overall, 4,237 patients were identified in the database, of whom 717 were analysed in each treatment arm after matching for baseline characteristics. At 30 days, VIV TAVR resulted in lower rates of the composite of all-cause mortality, all-cause stroke, myocardial infarction, and major or life-threatening bleeding (odds ratio [OR], 0.62, 95 percent confidence interval [CI], 0.44–0.88; p=0.03).

No significant between-group difference was observed for the combined endpoint of cardiovascular death, all-cause stroke, myocardial infarction, or rehospitalization for heart failure (OR, 1.18, 95 percent CI, 0.99–1.41; p=0.26) during a median follow-up of 516 days.

However, patients in the VIV TAVR group were more frequently rehospitalized for heart failure and pacemaker implantation. Moreover, a time-dependent interaction was reported between all-cause and cardiovascular mortality following VIV TAVR (pinteraction<0.05).

“VIV TAVR and redo SAVR represent the two treatments for aortic bioprosthesis failure,” the investigators said. “Clinical comparison of both therapies remains limited by the number of patients analysed.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 5 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 22 hours ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.